GALAPAGOS GENOMICS WKN: A0EAT9 ISIN: BE0003818359 Kürzel: GLPG Forum: Aktien Thema: Hauptdiskussion

Galapagos reports FY 2022 results, sees further reduction of cash burn in FY 2023 https://seekingalpha.com/news/3940356-galapagos-reports-fy-2022-results-sees-further-reduction-of-cash-burn-in-fy-2023 • Galapagos press release (NASDAQ:GLPG): FY GAAP EPS of -€3.32 misses by €2.21. • Revenue of €505.3M (+4.2% Y/Y) misses by €77M. • For FY 2023, co anticipates further reduction of its cash burn and anticipates landing between €380 and €420 million (compared to €514 million for FY 2022). • Anticipates between €140 and €160 million net sales of Jyseleca for FY 2023.

Galapagos announces full year 2022 results and outlook for 2023 https://www.globenewswire.com/news-release/2023/02/23/2614774/0/en/Galapagos-announces-full-year-2022-results-and-outlook-for-2023.html

Jefferies Upgrades Galapagos to Hold, Lowers Price Target to $47.2 https://www.benzinga.com/news/23/01/30518170/jefferies-upgrades-galapagos-to-hold-lowers-price-target-to-47-2 Jefferies analyst Peter Welford upgrades Galapagos (NASDAQ:GLPG) from Underperform to Hold and lowers the price target from $49 to $47.2.

https://finance.yahoo.com/news/galapagos-announces-changes-executive-committee-210100169.html

Belgian biotech company Galapagos on the hunt for deals https://www.ft.com/content/06c089ca-8810-493d-ab40-c3fa02ff8779 Former Johnson & Johnson executive ‘on the look out’ for rivals amid biotech sell-off The former chief scientific officer of Johnson & Johnson is on the hunt for acquisitions after he took the reins at the struggling Belgian biotech Galapagos this year. Paul Stoffels is on a “mission” to reinstate Galapagos as a top European biotech player. He has returned to lead the company he co-founded in 1999, attracted to its strong balance sheet of €4.4bn in cash and current financial investments, and he is seeking to spread access to innovative cancer treatments in Europe. Stoffels said he was on the “look out” for companies with good drugs that had not yet reached human trials or were in the early stages that Galapagos could accelerate to market. After the worst biotech sell-off since the early 2000s, he said valuations were starting to appear attractive. ... But in a biotech downturn, he must convince investors that the company, with a market capitalisation of €2.5bn, should be valued at more than the cash on its balance sheet. He said he would like to see the market capitalisation above the cash balance next year. ...

https://www.globenewswire.com/news-release/2022/12/13/2572346/0/en/Galapagos-and-CellPoint-presented-encouraging-initial-data-at-ASH-2022-for-GLPG5101-a-CD19-CAR-T-candidate-manufactured-at-point-of-care.html

Nur noch verrückt der Kurs .. wer das Ding übernimmt bekommt bald 2 Mrd Cash oben drauf 🫣🤣

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors https://www.globenewswire.com/news-release/2022/11/11/2554147/0/en/Galapagos-announces-CHMP-adoption-of-PRAC-s-recommendation-for-Jyseleca-following-extensive-safety-review-of-all-JAK-inhibitors.html

Sehen jedenfalls nur wenige 😉

Sehe ich das richtig? Cash 4,4 Mrd MK 2,8 Mrd Keine Schulden ?

Galapagos GAAP EPS of -€0.16, revenue of €410.2M https://seekingalpha.com/news/3901452-galapagos-gaap-eps-of-016-revenue-of-4102m?utm_source=feed_news_all&utm_medium=referral • Galapagos press release (NASDAQ:GLPG): 9M  GAAP EPS of -€0.16. • Revenue of €410.2M (+29.0% Y/Y). • Clear path forward for accelerated growth and value creation • Reshape innovation model and build fit-for-purpose organization in key strategic therapeutic areas: immunology and oncology • Jyseleca® 2022 net sales guidance further increased to €80-€90 million from €75-€85 million at H1 2022. • Cash and current financial investments of €4.4 billion on 30 September.

Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results https://www.globenewswire.com/news-release/2022/11/03/2548247/0/en/Galapagos-announces-strategy-to-accelerate-innovation-and-reports-strong-third-quarter-2022-results.html

Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies https://www.globenewswire.com/news-release/2022/10/03/2527295/0/en/Galapagos-receives-positive-CHMP-opinion-for-Jyseleca-European-label-update-based-on-testicular-function-safety-data-from-MANTA-RAy-studies.html

First key steps in pipeline rebuild and strong commercial progress in H1 2022 https://www.globenewswire.com/news-release/2022/08/04/2492746/0/en/First-key-steps-in-pipeline-rebuild-and-strong-commercial-progress-in-H1-2022.html

Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies "https://www.globenewswire.com/news-release/2022/06/21/2466613/0/en/Galapagos-to-acquire-CellPoint-and-AboundBio-to-accelerate-access-to-next-generation-cell-therapies.html • Potential for paradigm shift in CAR-T therapy with CellPoint’s decentralized point-of-care manufacturing model, in partnership with Lonza, and AboundBio’s cutting-edge fully human antibody-based capabilities, providing a platform of next-generation CAR-Ts and bispecific antibodies • Clinical validation of decentralized production platform with CD19 CAR-T in 2 Phase 1/2a studies in relapsed/refractory Non-Hodgkin’s-Lymphoma (rrNHL) and Chronic Lymphocytic Leukemia (rrCLL) ongoing, with topline results expected in H1 2023 • Positions Galapagos in next-generation cancer therapy market and significantly broadens portfolio and capabilities • All cash acquisition of CellPoint for an upfront amount of €125 million, with milestone payments up to €100 million and AboundBio for $14 million  Webcast presentation tomorrow, Wednesday, 22 June 2022, at 14.00 CET / 8 AM ET, www.glpg.com ...

https://www.businesswire.com/news/home/20220524005319/en/Galapagos-In-licenses-Novel-Drug-Targets-for-Inflammatory-Bowel-Disease-Discovered-by-Scipher-Medicine%E2%80%99s-Spectra%E2%84%A2-Platform